Item does not contain fulltextOBJECTIVE: To estimate the risk of breast cancer associated with diagnostic radiation in carriers of BRCA1/2 mutations. DESIGN: Retrospective cohort study (GENE-RAD-RISK). SETTING: Three nationwide studies (GENEPSO, EMBRACE, HEBON) in France, United Kingdom, and the Netherlands, PARTICIPANTS: 1993 female carriers of BRCA1/2 mutations recruited in 2006-09. MAIN OUTCOME MEASURE: Risk of breast cancer estimated with a weighted Cox proportional hazards model with a time dependent individually estimated cumulative breast dose, based on nominal estimates of organ dose and frequency of self reported diagnostic procedures. To correct for potential survival bias, the analysis excluded carriers who were diagnosed more th...
To access Publisher full text version of this article. Please click on the hyperlink in Additional L...
CONTEXT: The risk of breast cancer in BRCA1 and BRCA2 mutation carriers has been examined in many st...
IMPORTANCE: Limited information about the relationship between specific mutations in BRCA1 or BRCA2 ...
Objective To estimate the risk of breast cancer associated with diagnostic radiation in carriers of ...
PURPOSE: Women who carry germline mutations in the BRCA1 and BRCA2 genes are at greatly increased ri...
Background: The effects of low-dose medical radiation on breast cancer risk are uncertain, and few s...
Item does not contain fulltextImportance: The clinical management of BRCA1 and BRCA2 mutation carrie...
Fulltext embargoed for: 12 months post date of publicationBACKGROUND: The effects of low-dose medica...
Item does not contain fulltextBACKGROUND: We aimed to quantify previously observed relatively high c...
Contains fulltext : 89429.pdf (publisher's version ) (Closed access)We assessed re...
IntroductionRadiation exposure at a young age is one of the strongest risk factors for breast cancer...
Purpose: To undertake the first substantial clinical study of breast radiotherapy toxicity in BRCA1 ...
Background: We aimed to quantify previously observed relatively high cancer risks in BRCA2 mutation ...
Item does not contain fulltextBACKGROUND: It is recommended that BRCA1/2 mutation carriers undergo b...
Introduction: Radiation exposure at a young age is one of the strongest risk factors for breast canc...
To access Publisher full text version of this article. Please click on the hyperlink in Additional L...
CONTEXT: The risk of breast cancer in BRCA1 and BRCA2 mutation carriers has been examined in many st...
IMPORTANCE: Limited information about the relationship between specific mutations in BRCA1 or BRCA2 ...
Objective To estimate the risk of breast cancer associated with diagnostic radiation in carriers of ...
PURPOSE: Women who carry germline mutations in the BRCA1 and BRCA2 genes are at greatly increased ri...
Background: The effects of low-dose medical radiation on breast cancer risk are uncertain, and few s...
Item does not contain fulltextImportance: The clinical management of BRCA1 and BRCA2 mutation carrie...
Fulltext embargoed for: 12 months post date of publicationBACKGROUND: The effects of low-dose medica...
Item does not contain fulltextBACKGROUND: We aimed to quantify previously observed relatively high c...
Contains fulltext : 89429.pdf (publisher's version ) (Closed access)We assessed re...
IntroductionRadiation exposure at a young age is one of the strongest risk factors for breast cancer...
Purpose: To undertake the first substantial clinical study of breast radiotherapy toxicity in BRCA1 ...
Background: We aimed to quantify previously observed relatively high cancer risks in BRCA2 mutation ...
Item does not contain fulltextBACKGROUND: It is recommended that BRCA1/2 mutation carriers undergo b...
Introduction: Radiation exposure at a young age is one of the strongest risk factors for breast canc...
To access Publisher full text version of this article. Please click on the hyperlink in Additional L...
CONTEXT: The risk of breast cancer in BRCA1 and BRCA2 mutation carriers has been examined in many st...
IMPORTANCE: Limited information about the relationship between specific mutations in BRCA1 or BRCA2 ...